| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The prevalence of drug-resistant Acinetobacter spp. has increased and is a serious concern worldwide. The aims of this study were to clarify species-level identification, antibiotic susceptibilities, and mechanisms of carbapenem resistant of Acinetobacter spp. using 60 Acinetobacter clinical isolates from sputum specimens in Japan. Genomic species were identified by sequencing of the rpoB gene. MICs were determined by the agar dilution method following CLSI guidelines (M100-S25). Carbapenemase genes and the genetic environment were investigated by PCR and DNA sequencing. Five Acinetobacter spp. isolates were resistant to carbapenem and encoded the IMP-34 gene. These five strains harboured a class 1 integron and carried a gene cassettes. In this study, we described the distribution and species level identification of Acinetobacter spp. isolated from sputum specimens in Japan. These included IMP-34 producers, which is the first detection of IMP-34 among Acinetobacter spp.
|
